Modern management of perianal fistulas in Crohn's disease: future directions

Paulo Gustavo Kotze, Bo Shen, Amy Lightner, Takayuki Yamamoto, Antonino Spinelli, Subrata Ghosh, Remo Panaccione

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Perianal fistulae in patients with Crohn's disease (CD) can be associated with significant morbidity resulting in negative impact on quality of life. The last two decades have seen significant advancements in the management of perianal fistulas in CD, which has evolved into a multidisciplinary approach that includes gastroenterologists, colorectal surgeons, endoscopists and radiologists. Despite the introduction of new medical therapies such as antitumour necrosis factor and novel models of care delivery, the best fistula healing rates reported with combined medical and surgical approaches are approximately 50%. More recently, newer biologics, cell-based therapies as well as novel endoscopic and surgical techniques have been introduced raising new hopes that outcomes can be improved upon. In this review, we describe the modern management and the most recent advances in the management of complex perianal fistulising CD, which will likely impact clinical practice. We will explore optimal use of both older and newer biological agents, as well as new data on cell-based therapies. In addition, new techniques in endoscopic and surgical approaches will be discussed.

Original languageEnglish (US)
Pages (from-to)1181-1194
Number of pages14
JournalGut
Volume67
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Crohn Disease
Fistula
Cell- and Tissue-Based Therapy
Biological Factors
Biological Products
Necrosis
Quality of Life
Morbidity
Direction compound
Therapeutics
Gastroenterologists
Radiologists
Surgeons

Keywords

  • biologics
  • colorectal surgery
  • crohn’s disease
  • perianal fistula
  • therapeutic endoscopy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Kotze, P. G., Shen, B., Lightner, A., Yamamoto, T., Spinelli, A., Ghosh, S., & Panaccione, R. (2018). Modern management of perianal fistulas in Crohn's disease: future directions. Gut, 67(6), 1181-1194. https://doi.org/10.1136/gutjnl-2017-314918

Modern management of perianal fistulas in Crohn's disease : future directions. / Kotze, Paulo Gustavo; Shen, Bo; Lightner, Amy; Yamamoto, Takayuki; Spinelli, Antonino; Ghosh, Subrata; Panaccione, Remo.

In: Gut, Vol. 67, No. 6, 01.06.2018, p. 1181-1194.

Research output: Contribution to journalReview article

Kotze, PG, Shen, B, Lightner, A, Yamamoto, T, Spinelli, A, Ghosh, S & Panaccione, R 2018, 'Modern management of perianal fistulas in Crohn's disease: future directions', Gut, vol. 67, no. 6, pp. 1181-1194. https://doi.org/10.1136/gutjnl-2017-314918
Kotze PG, Shen B, Lightner A, Yamamoto T, Spinelli A, Ghosh S et al. Modern management of perianal fistulas in Crohn's disease: future directions. Gut. 2018 Jun 1;67(6):1181-1194. https://doi.org/10.1136/gutjnl-2017-314918
Kotze, Paulo Gustavo ; Shen, Bo ; Lightner, Amy ; Yamamoto, Takayuki ; Spinelli, Antonino ; Ghosh, Subrata ; Panaccione, Remo. / Modern management of perianal fistulas in Crohn's disease : future directions. In: Gut. 2018 ; Vol. 67, No. 6. pp. 1181-1194.
@article{733d20a3dd0045ac986d430dc4d5ea63,
title = "Modern management of perianal fistulas in Crohn's disease: future directions",
abstract = "Perianal fistulae in patients with Crohn's disease (CD) can be associated with significant morbidity resulting in negative impact on quality of life. The last two decades have seen significant advancements in the management of perianal fistulas in CD, which has evolved into a multidisciplinary approach that includes gastroenterologists, colorectal surgeons, endoscopists and radiologists. Despite the introduction of new medical therapies such as antitumour necrosis factor and novel models of care delivery, the best fistula healing rates reported with combined medical and surgical approaches are approximately 50{\%}. More recently, newer biologics, cell-based therapies as well as novel endoscopic and surgical techniques have been introduced raising new hopes that outcomes can be improved upon. In this review, we describe the modern management and the most recent advances in the management of complex perianal fistulising CD, which will likely impact clinical practice. We will explore optimal use of both older and newer biological agents, as well as new data on cell-based therapies. In addition, new techniques in endoscopic and surgical approaches will be discussed.",
keywords = "biologics, colorectal surgery, crohn’s disease, perianal fistula, therapeutic endoscopy",
author = "Kotze, {Paulo Gustavo} and Bo Shen and Amy Lightner and Takayuki Yamamoto and Antonino Spinelli and Subrata Ghosh and Remo Panaccione",
year = "2018",
month = "6",
day = "1",
doi = "10.1136/gutjnl-2017-314918",
language = "English (US)",
volume = "67",
pages = "1181--1194",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - Modern management of perianal fistulas in Crohn's disease

T2 - future directions

AU - Kotze, Paulo Gustavo

AU - Shen, Bo

AU - Lightner, Amy

AU - Yamamoto, Takayuki

AU - Spinelli, Antonino

AU - Ghosh, Subrata

AU - Panaccione, Remo

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Perianal fistulae in patients with Crohn's disease (CD) can be associated with significant morbidity resulting in negative impact on quality of life. The last two decades have seen significant advancements in the management of perianal fistulas in CD, which has evolved into a multidisciplinary approach that includes gastroenterologists, colorectal surgeons, endoscopists and radiologists. Despite the introduction of new medical therapies such as antitumour necrosis factor and novel models of care delivery, the best fistula healing rates reported with combined medical and surgical approaches are approximately 50%. More recently, newer biologics, cell-based therapies as well as novel endoscopic and surgical techniques have been introduced raising new hopes that outcomes can be improved upon. In this review, we describe the modern management and the most recent advances in the management of complex perianal fistulising CD, which will likely impact clinical practice. We will explore optimal use of both older and newer biological agents, as well as new data on cell-based therapies. In addition, new techniques in endoscopic and surgical approaches will be discussed.

AB - Perianal fistulae in patients with Crohn's disease (CD) can be associated with significant morbidity resulting in negative impact on quality of life. The last two decades have seen significant advancements in the management of perianal fistulas in CD, which has evolved into a multidisciplinary approach that includes gastroenterologists, colorectal surgeons, endoscopists and radiologists. Despite the introduction of new medical therapies such as antitumour necrosis factor and novel models of care delivery, the best fistula healing rates reported with combined medical and surgical approaches are approximately 50%. More recently, newer biologics, cell-based therapies as well as novel endoscopic and surgical techniques have been introduced raising new hopes that outcomes can be improved upon. In this review, we describe the modern management and the most recent advances in the management of complex perianal fistulising CD, which will likely impact clinical practice. We will explore optimal use of both older and newer biological agents, as well as new data on cell-based therapies. In addition, new techniques in endoscopic and surgical approaches will be discussed.

KW - biologics

KW - colorectal surgery

KW - crohn’s disease

KW - perianal fistula

KW - therapeutic endoscopy

UR - http://www.scopus.com/inward/record.url?scp=85050985743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050985743&partnerID=8YFLogxK

U2 - 10.1136/gutjnl-2017-314918

DO - 10.1136/gutjnl-2017-314918

M3 - Review article

C2 - 29331943

AN - SCOPUS:85050985743

VL - 67

SP - 1181

EP - 1194

JO - Gut

JF - Gut

SN - 0017-5749

IS - 6

ER -